Abstract
Background: Glucocorticoids (GCs) are largely used in different inflammatory, autoimmune and proliferative diseases. To date their mechanism of action is not completely clear and more studies are necessary, in particular to explain the great interindividual variability in clinical response. In this panorama the glucocorticoid receptor (GR) has an important role: in fact it regulates the pharmacological response thanks to the capability to interact with different molecules (DNA, RNA, ncRNA and proteins) that are known to influence its activity.
Results: In this review our aim is to highlight the knowledge about the role of protein-protein, RNAprotein interactions and epigenetic modifications on the GR and the consequent response to GCs. The characteristics of these interactions with the GR and their effects on the pharmacological activity of GCs will be examined. Conclusion: This information could contribute to the prediction of individual sensitivity to steroids through the identification of new markers of GC resistance. In addition this knowledge may be used in developing new strategies for targeted therapy.Keywords: Biomarkers, epigenetic, glucocorticoid, glucocorticoid receptor, protein-protein interactions, RNA-protein interactions, sensitivity.
Mini-Reviews in Medicinal Chemistry
Title:Glucocorticoid Receptor Interacting Co-regulators: Putative Candidates for Future Drug Targeting Therapy
Volume: 17 Issue: 8
Author(s): Alessia Di Silvestre, Marianna Lucafo, Sara De Iudicibus, Alessandro Ventura, Stefano Martelossi, Gabriele Stocco and Giuliana Decorti*
Affiliation:
- Department of Life Sciences, University of Trieste, Via Alexander Fleming, 22, 34127 Trieste,Italy
Keywords: Biomarkers, epigenetic, glucocorticoid, glucocorticoid receptor, protein-protein interactions, RNA-protein interactions, sensitivity.
Abstract: Background: Glucocorticoids (GCs) are largely used in different inflammatory, autoimmune and proliferative diseases. To date their mechanism of action is not completely clear and more studies are necessary, in particular to explain the great interindividual variability in clinical response. In this panorama the glucocorticoid receptor (GR) has an important role: in fact it regulates the pharmacological response thanks to the capability to interact with different molecules (DNA, RNA, ncRNA and proteins) that are known to influence its activity.
Results: In this review our aim is to highlight the knowledge about the role of protein-protein, RNAprotein interactions and epigenetic modifications on the GR and the consequent response to GCs. The characteristics of these interactions with the GR and their effects on the pharmacological activity of GCs will be examined. Conclusion: This information could contribute to the prediction of individual sensitivity to steroids through the identification of new markers of GC resistance. In addition this knowledge may be used in developing new strategies for targeted therapy.Export Options
About this article
Cite this article as:
Di Silvestre Alessia, Lucafo Marianna, De Iudicibus Sara, Ventura Alessandro, Martelossi Stefano, Stocco Gabriele and Decorti Giuliana*, Glucocorticoid Receptor Interacting Co-regulators: Putative Candidates for Future Drug Targeting Therapy, Mini-Reviews in Medicinal Chemistry 2017; 17 (8) . https://dx.doi.org/10.2174/1389557516666161130094255
DOI https://dx.doi.org/10.2174/1389557516666161130094255 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combination Therapy with Arsenic Trioxide for Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Interferon Alpha2 in the Treatment of Hematological Malignancies. Status and Perspectives (Guest Editor: Hans Carl Hasselbalch)]
Current Drug Targets Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Recent Developments in Taxane Drug Delivery
Current Drug Delivery An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Current Medicinal Chemistry The Coagulation Cascade in Sepsis
Current Pharmaceutical Design Galectin-9 in Cancer Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly
Current Medicinal Chemistry The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma
Current Drug Targets AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Drug Metabolism Letters Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery
Current Drug Targets Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery “Cancer Antigen WT1 Protein-Derived Peptide”-Based Treatment of Cancer -Toward the Further Development
Current Medicinal Chemistry Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT
Current Medicinal Chemistry Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
Medicinal Chemistry Protein Kinase C Modulates Aurora-kinase Inhibition Induced by CCT129202 in HMC-1560,816 Cell Line
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry